Admission diagnoses of patients later diagnosed with autoimmune encephalitis.
Admission diagnosis
Autoimmune encephalitis
Manifestation symptoms
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
24
08
2018
accepted:
25
10
2018
revised:
23
10
2018
pubmed:
14
11
2018
medline:
8
5
2019
entrez:
14
11
2018
Statut:
ppublish
Résumé
Since the detection of autoantibodies against neuronal surface antigens, autoimmune encephalitis (AE) has been more frequently diagnosed, especially in patients with symptoms typical of limbic encephalitis, such as seizures, short-term memory deficits, or psychosis. However, the clinical spectrum of AE may be much wider, making correct clinical diagnosis difficult. We retrospectively analysed symptoms and admission diagnoses at first clinical presentation in 50 AE patients. We included patients with a clinical diagnosis of AE for whom a FDG-PET imaging was available. Final diagnoses were re-evaluated by a blinded investigator according to the most recent consensus suggestions published in 2016 for AE diagnostic criteria. We additionally describe two patients with Morvan syndrome who showed CASPR2 antibodies. In 40 patients (80.0%), the clinical presentation at first admission was typical for AE. Ten patients (20.0%) initially suffered from atypical symptoms; among these patients, isolated headache and cerebellar dysfunction were most frequent (three patients each). However, an initial diagnosis of suspected encephalitis was only reached in 16 patients (32.0%), nine (18.0) of which were suspected to have infectious encephalitis, and seven (14.0%) patients were suspected to have AE. In 34 patients (68.0%), a diagnosis other than encephalitis was considered, (e.g., epilepsy, psychiatric diseases, transient ischemic attack, dementia, meningitis, and cerebellitis). These data show the broad spectrum of initial symptoms of AE; the correct initial diagnosis of AE is often missed or delayed. Hence, clinicians in neurological and psychiatric hospitals should consider AE in the differential diagnosis of cases with atypical clinical presentations.
Sections du résumé
BACKGROUND
BACKGROUND
Since the detection of autoantibodies against neuronal surface antigens, autoimmune encephalitis (AE) has been more frequently diagnosed, especially in patients with symptoms typical of limbic encephalitis, such as seizures, short-term memory deficits, or psychosis. However, the clinical spectrum of AE may be much wider, making correct clinical diagnosis difficult.
METHODS
METHODS
We retrospectively analysed symptoms and admission diagnoses at first clinical presentation in 50 AE patients. We included patients with a clinical diagnosis of AE for whom a FDG-PET imaging was available. Final diagnoses were re-evaluated by a blinded investigator according to the most recent consensus suggestions published in 2016 for AE diagnostic criteria. We additionally describe two patients with Morvan syndrome who showed CASPR2 antibodies.
RESULTS
RESULTS
In 40 patients (80.0%), the clinical presentation at first admission was typical for AE. Ten patients (20.0%) initially suffered from atypical symptoms; among these patients, isolated headache and cerebellar dysfunction were most frequent (three patients each). However, an initial diagnosis of suspected encephalitis was only reached in 16 patients (32.0%), nine (18.0) of which were suspected to have infectious encephalitis, and seven (14.0%) patients were suspected to have AE. In 34 patients (68.0%), a diagnosis other than encephalitis was considered, (e.g., epilepsy, psychiatric diseases, transient ischemic attack, dementia, meningitis, and cerebellitis).
CONCLUSIONS
CONCLUSIONS
These data show the broad spectrum of initial symptoms of AE; the correct initial diagnosis of AE is often missed or delayed. Hence, clinicians in neurological and psychiatric hospitals should consider AE in the differential diagnosis of cases with atypical clinical presentations.
Identifiants
pubmed: 30421340
doi: 10.1007/s00415-018-9105-3
pii: 10.1007/s00415-018-9105-3
doi:
Substances chimiques
Antibodies
0
Biomarkers
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
124-132Références
Lancet Neurol. 2013 Feb;12(2):157-65
pubmed: 23290630
Exp Ther Med. 2015 Oct;10(4):1283-1292
pubmed: 26622479
Neurology. 2016 May 3;86(18):1692-9
pubmed: 27037230
Neurology. 2012 Jul 10;79(2):195-6
pubmed: 22744657
Dev Med Child Neurol. 2014 Aug;56(8):794-6
pubmed: 24641688
Front Psychiatry. 2017 Feb 16;8:25
pubmed: 28261116
Neurology. 2011 Jul 12;77(2):179-89
pubmed: 21747075
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
Ann Indian Acad Neurol. 2013 Oct;16(4):577-84
pubmed: 24339583
J Neuroimmunol. 2013 Mar 15;256(1-2):94-6
pubmed: 23332614
J Neurol Neurosurg Psychiatry. 2012 Jun;83(6):638-45
pubmed: 22448032
Neurology. 2012 Sep 11;79(11):1136-44
pubmed: 22895588
Lancet Neurol. 2011 Aug;10(8):759-72
pubmed: 21777830
Curr Neurol Neurosci Rep. 2013 May;13(5):348
pubmed: 23526548
Neurology. 2016 Dec 6;87(23):2471-2482
pubmed: 27920282
Headache. 2016 Jun;56(6):995-1003
pubmed: 27241874
Lancet Neurol. 2011 Jan;10(1):63-74
pubmed: 21163445
Ann Neurol. 2014 Mar;75(3):411-28
pubmed: 24700511
Lancet Neurol. 2008 Dec;7(12):1091-8
pubmed: 18851928
Neurol Sci. 2014 Jan;35(1):125-6
pubmed: 23892978